CGTLive®’s Weekly Rewind – January 31, 2025

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications

The planned phase 1 RESOLUTION study will include patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.

2. Barry J Byrne, MD, PhD, on MDA’s Upcoming 2025 Clinical & Scientific Conference

The chief medical advisor of the Muscular Dystrophy Association discussed what attendees can expect at the 2025 MDA Meeting.

3. Sarepta’s DMD Gene Therapy Elevidys Shows Sustained Benefit in Updated Phase 3 Data

With regard to safety, the company stated that no new safety signals have been reported.

4. Evaluating Lyell’s CAR-T IMPT-314 in LBCL

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.

5. uniQure Makes Progress in Trial for SOD1-ALS Gene Therapy AMT-162

The company received a recommendation from the study’s IDMC to move onto enrollment for the trial’s second cohort.